Framework for the cost-effectiveness of secondary prevention strategies in cardiovascular diseases: A Canadian theoretical modelbased analysis

To estimate the relative risk reduction threshold for adding a novel expensive lipid-lowering therapy (NT) to standard therapy, in a secondary prevention population intolerant to high doses of statins, using a cost-effectiveness analysis from the Canadian Provincial Ministries of Health perspective (single-payer system).